Member Info for Titania

"However, determining the clinical efficacy of an intervention in the face of changes in in vitro activity through new clinical trials is not feasible given the rate of SARS-CoV-2 evolution. A consensus on alternative approaches to evaluation is therefore required."

https://www.gov.uk/government/publications/responding-to-emerging-covid-19-variants-of-concern/responding-to-emerging-covid-19-variants-of-concern

https://twitter.com/Synairgenplc/with_replies?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

From Brooke

No it is not. There is a medical affairs contract role with Ashfield that is legitimate; there is no commercial opening. We will look into who has posted this and try to have it removed.

Sage Covid-19 registration of participants interests:-
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/971151/Covid-19_SAGE_register_of_participants__interests.pdf

GSK pumps £30m into a new Oxford University partnership
https://pharmaphorum.com/news/gsk-pumps-30m-into-a-new-oxford-university-institute/

I am still so disappointed that SNG001 was not given a chance on the Recovery Trial and what absolutely amazes me is that GSK spending 30 million on the building/collaboration at Nuffield Medical school in Oxford is not declared as a potential conflict of interest in government submissions by Horby!

Using google translate:-
"The presence of these autoantibodies has been confirmed in several other articles, as well as in patients with the APS-1 autoimmune syndrome. More recently, we have developed more sensitive tests, and found that these auto-Abs can explain up to 20% of severe cases over 80 and/or death. Taken together, these two findings underscore the major role of the IFN type I pathway in the development of severe Covid-19. They open up new treatment pathways based on type I IFN not targeted by autoantibodies such as IFN-b. We are continuing to search for other genetic defects responsible for severe Covid-19 as part of this project. The presence of these autoantibodies has been confirmed in several other articles, as well as in patients with the autoantibodies syndrome -immune APS-1. More recently, we have developed more sensitive tests, and found that these auto-Abs can explain up to 20% of severe cases over 80 and/or death. Taken together, these two findings underscore the major role of the IFN type I pathway in the development of severe Covid-19. They open up new treatment pathways based on type I IFN not targeted by autoantibodies such as IFN-b. We are continuing to search for other genetic defects responsible for severe Covid-19 as part of this project.Paul Bastard
@APHP
presents the results of the #ANR GENCOVID project which underline the major role of type 1 interferon in the development of severe forms of #Covid19 and open up new avenues of treatment. http://bit.ly/3HPCp10
P.176: http://bit.ly/3JwKLfn"

https://twitter.com/search?q=%23COVID19%20interferon%20ANR&src=typed_query&f=live

Apologies if already posted.

"Some companies have accumulated pseudo- and authentic-virus data on most viral variants to date and demonstrated consistency between the two for their molecule, which may increase confidence in future pseudovirus assays for these medicines. Where possible, pseudovirus assays should be shown to be representative of live virus outcomes prior to relying upon them for decision making. The UK Health Security Agency has offered to share virus isolates with companies to aid with the standardisation of testing compounds against new variants."

https://www.gov.uk/government/publications/responding-to-emerging-covid-19-variants-of-concern/responding-to-emerging-covid-19-variants-of-concern

Almost positive!

"Conclusion: If the encouraging signal in the relative risk of disease progression or death (~30% reduction) observed in this 300 patient/arm trial were confirmed in a larger trial, SNG001 could become a useful treatment option for hospitalised COVID-19 patients."

https://erj.ersjournals.com/content/60/suppl_66/RCT2884

Apologies if already posted.

https://twitter.com/Synairgenplc

The World Health Organization keeps a list of viruses and bacteria with pandemic potential and MERS and SARS are on it!

https://www.npr.org/sections/goatsandsoda/2023/01/29/1151039454/9-diseases-virus-epidemiologists-pandemic-potential-who

SNG001 needed to combat MERS and so the Arab world is likely to be very interested!

https://twitter.com/RickABright/with_replies?lang=en

Looks like Rick Bright does chat to Peter Horby on twitter maybe he could beg for us to get on the recovery trial!

If we get a P3 but with a instant massive cash injection a la Verona Pharma no one here will be happy.

Could this be SNG?

"Exciting new antiviral treatments have been developed that have so far been tested in smaller studies in mostly unvaccinated people. We we do not yet know how effective these treatments will be in the general UK population which is largely vaccinated, so we need to do more studies to find this out."

https://www.panoramictrial.org/participant-information

Placebo hamsters not inhaling steroids i don't think.

https://finance.yahoo.com/news/biondvax-innovative-inhaled-anti-sars-112500567.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAANEsnEiCZR777Ob1yhlHTEX075UCvH4tEKrLL_Ahh2C0niFIRO7cSvLqyxz1vUncTpW-VtS_Itd3C0uOCdvTI7WhI4IiwiPq48rwGP24_vSG1GnVLe7b5j4akPhKw64FFUST2ZwJC3OkAeezcIhpGBP_Fdo_Sf8e69E6eK_tJDzz

Could SNG001 be used in this way as well?
Apologies if already posted.

"In conclusion, we present compelling evidence that COVID-19 is a type of sepsis based on the dysregulation of specific gene expression signatures, with unique COVID-19 specific immune responses also contributing to patient severity. When exploring the expression of previously-described12 all-cause sepsis signatures in a broad spectrum of COVID-19 patients, severely ill patients displayed significant dysregulation of these genes. Furthermore, several COVID-19 gene expression responses have known roles in sepsis pathogenesis, including various inflammatory pathways, neutrophil degranulation, interferon a/ß signaling and heme metabolism. This can provide prognostic criteria as well as a precision medicine approach to characterize (and possibly treat) the disease. In conclusion, future opportunities for the clinical management of Covid-19 patients can draw from existing and under-development prognostic tools relevant to all-cause sepsis signatures and therapeutic options that emphasize address a dysregulated host immune response."

https://www.nature.com/articles/s41598-023-28259-y

Interferon B mentioned. Apologies if already posted.

Moderna reports 83.7% efficacy for 60+ in RSV vaccine trial so 16.3% potential to treat!
Plus the ones who choose not to be vaccinated.

6.3https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-mRNA-1345-an-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Has-Met-Primary-Efficacy-Endpoints-in-Phase-3-Trial-in-Older-Adults/default.aspx

"Despite progress in breakthroughs and therapies, much remains to be done to fix our fragmented global healthcare system."

https://twitter.com/RickABright/status/1615312577357021184?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet